These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 15007629)
21. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
22. [Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)]. Ivanov VT; Andronova TM; Nesmeianov VA; Pinegin BV; Ledger P; Bomford R; Khaitov RM Klin Med (Mosk); 1997; 75(3):11-5. PubMed ID: 9229604 [No Abstract] [Full Text] [Related]
23. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Namazi MR Int Immunopharmacol; 2004 Mar; 4(3):349-53. PubMed ID: 15037212 [TBL] [Abstract][Full Text] [Related]
24. [Immunological disorders and their correction with thymalin in the surgical treatment of patients with 1st and 2nd branchial arch syndromes]. Kotov GA; Iarchuk NI; Khavinson VKh; Morozov VG Stomatologiia (Mosk); 1984; 63(3):43-4. PubMed ID: 6589825 [No Abstract] [Full Text] [Related]
25. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138 [TBL] [Abstract][Full Text] [Related]
26. Role of helminths in regulating mucosal inflammation. Weinstock JV; Summers RW; Elliott DE Springer Semin Immunopathol; 2005 Sep; 27(2):249-71. PubMed ID: 15959781 [TBL] [Abstract][Full Text] [Related]
27. Atopic dermatitis: immunobiology and treatment with immune modulators. Leung DY Clin Exp Immunol; 1997 Jan; 107 Suppl 1():25-30. PubMed ID: 9020932 [TBL] [Abstract][Full Text] [Related]
28. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. McGonagle D; Aziz A; Dickie LJ; McDermott MF Pediatr Res; 2009 May; 65(5 Pt 2):38R-45R. PubMed ID: 19190531 [TBL] [Abstract][Full Text] [Related]
29. Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Marks DJ Curr Opin Gastroenterol; 2011 Jul; 27(4):328-34. PubMed ID: 21483259 [TBL] [Abstract][Full Text] [Related]
31. The innate immune system and inflammatory bowel disease. Davies JM; Abreu MT Scand J Gastroenterol; 2015 Jan; 50(1):24-33. PubMed ID: 25523553 [TBL] [Abstract][Full Text] [Related]
32. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446 [TBL] [Abstract][Full Text] [Related]
33. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
34. Inflammatory bowel disease: maladaptation of the vigilant genotype in a hyper-clean world? Rajan TV Perspect Biol Med; 2006; 49(2):171-7. PubMed ID: 16702702 [TBL] [Abstract][Full Text] [Related]
35. Hygiene and other early childhood influences on the subsequent function of the immune system. Rook GA Dig Dis; 2011; 29(2):144-53. PubMed ID: 21734378 [TBL] [Abstract][Full Text] [Related]
36. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081 [TBL] [Abstract][Full Text] [Related]
37. TLR2 agonists enhance CD8+Foxp3+ regulatory T cells and suppress Th2 immune responses during allergen immunotherapy. Tsai YG; Yang KD; Niu DM; Chien JW; Lin CY J Immunol; 2010 Jun; 184(12):7229-37. PubMed ID: 20483759 [TBL] [Abstract][Full Text] [Related]
38. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
39. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Faulds D; Goa KL; Benfield P Drugs; 1993 Jun; 45(6):953-1040. PubMed ID: 7691501 [TBL] [Abstract][Full Text] [Related]
40. PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2. Xu Y; Yang E; Huang Q; Ni W; Kong C; Liu G; Li G; Su H; Wang H J Mol Med (Berl); 2015 Jun; 93(6):645-62. PubMed ID: 25586105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]